1. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R (2013) Blood 121(8): 1367-76
    › Primary publication · 23297127 (PubMed) · PMC3578953 (PubMed Central)
  2. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA (2013) Blood 121(9): 1604-11
    › Primary publication · 23297126 (PubMed) · PMC3587323 (PubMed Central)
  3. Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A (2012) BMC Cancer : 478
    › Primary publication · 23072591 (PubMed) · PMC3519597 (PubMed Central)
  4. Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients. Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A (2012) Br J Haematol 159(5): 604-8
    › Primary publication · 23043253 (PubMed) · PMC3767388 (PubMed Central)
  5. Web-based analysis and publication of flow cytometry experiments. Kotecha N, Krutzik PO, Irish JM (2010) Curr Protoc Cytom : Unit10.17
    › Primary publication · 20578106 (PubMed) · PMC4208272 (PubMed Central)
  6. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R (2010) Proc Natl Acad Sci U S A 107(29): 12747-54
    › Primary publication · 20543139 (PubMed) · PMC2919949 (PubMed Central)
  7. WebFlow: a software package for high-throughput analysis of flow cytometry data. Hammer MM, Kotecha N, Irish JM, Nolan GP, Krutzik PO (2009) Assay Drug Dev Technol 7(1): 44-55
    › Primary publication · 19187010 (PubMed) · PMC2956679 (PubMed Central)
  8. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R (2009) Blood 114(16): 3431-8
    › Primary publication · 19641184 (PubMed) · PMC2765679 (PubMed Central)
  9. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML (2008) Cancer Cell 14(4): 335-43
    › Primary publication · 18835035 (PubMed) · PMC2647559 (PubMed Central)
  10. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS (2007) Blood 109(9): 3945-52
    › Primary publication · 17192389 (PubMed) · PMC1874575 (PubMed Central)